Table 1B.
DLI characteristics.
| Patient ID | DLI Trigger | Relapse triggering thLI (months post alloHSCT) | Anti-neoplastic treatment pre DLI |
Response to antineoplastic treatment pre DLI* | Days post antineoplastic treatment at 1st DLI | First DLI (months post alloHSCT) | Dose 1st DLI (CD3+/kg BW) | Collection method of 1st DLI | Total number DLI | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| 34 | Cytological R | 3 | Aza | SD | 14 | 4 | 1,6×106 | Cryopreserved unstimulated leukapheresis | 1 | ||
| 36 | Cytological R | 44 | FLA-IDA | SD | 29 | 45 | 1×107 | Fresh unstimulated leukapheresis | 1 | ||
| 38 | Cytological R | 27 | FLA-IDA | CRi, iHC | 35 | 28 | 1×107 | Cryopreserved unstimulated leukapheresis | 2 | ||
| 41 | Molecular R | 4 | FLA-IDA | PR | 29 | 6 | 1×107 | Fresh unstimulated leukapheresis | 2 | ||
| 42 | Cytological R | 46 | CLAEG | PR | 35 | 47 | 1×107 | Fresh unstimulated leukapheresis | 2 | ||
| 45 | Cytological R | 6 | DnR+AraC | CRi, iHC | 70 | 8 | 1,5×106 | Fresh unstimulated leukapheresis | 2 | ||
| 47 | Cytological R | 23 | FLA-IDA | CRi, iHC | 24 | 24 | 1×107 | Cryopreserved G-CSF stimulated leukapheresis | 2 | ||
| 48 | Cytological R | 12 | MEC | CRi, iHC | 42 | 13 | 5×106 | Fresh unstimulated leukapheresis | 3 | ||
| 49 | Cytological R | 2 | Aza + Ven | PR | 8 | 3 | 1×107 | Fresh unstimulated leukapheresis | 1 | ||
| 52 | Cytological R | 9 | Aza | PR | 8 | 11 | 1×107 | Fresh unstimulated leukapheresis | 1 | ||
| 53 | Cytological R | 12 | Aza | PR | 8 | 13 | 1×107 | Cryopreserved G-CSF stimulated leukapheresis | 2 | ||
| 54 | Cytological R | 24 | Aza | PR | 13 | 25 | 5×106 | Cryopreserved unstimulated leukapheresis | 2 | ||
| 56 | Molecular R | 2 | Aza + Sor | PR | 44 | 4 | 6×106 | Cryopreserved unstimulated leukapheresis | 2 | ||
alloHSCT, allogeneic hematopoietic stem cell transplantation; Aza, Azacitidine; BW, bodyweight; CLAEG, Cladribine + Cytarabine; CRi, complete remission with incomplete haematological recovery; Daunorubicin, CTx, chemotherapy; DLI, donor lymphocyte infusion; DnR/AraC, Daunorubicin + Cytarabine; FLA-IDA, Fludarabine + Cytarabine + Idarubicin; iHC, increased host chimerism; MEC, Mitoxantrone + Etoposide + Cytarabine; PR, partial remission; R, Relapse; RD, residual disease; Sor, Sorafenib; Ven, Venetoclax. *according to ELN response criteria (35).